MCID: VRL010
MIFTS: 59

Viral Hepatitis

Categories: Infectious diseases, Rare diseases, Liver diseases, Gastrointestinal diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Viral Hepatitis

MalaCards integrated aliases for Viral Hepatitis:

Name: Viral Hepatitis 12 51 3 14 69
Hepatitis, Viral, Animal 41 69
Unspecified Viral Hepatitis with Hepatic Coma 12
Viral Hepatitis with Hepatic Coma 12
Animal Viral Hepatitis 12
Human Viral Hepatitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1884
MeSH 41 D006524

Summaries for Viral Hepatitis

Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to non-a-e hepatitis and hepatitis a. An important gene associated with Viral Hepatitis is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Allograft rejection. The drugs Peginterferon alfa-2a and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and liver/biliary system

CDC : 3 Learn more about the ABCs of Hepatitis.

Wikipedia : 72 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute (recent... more...

Related Diseases for Viral Hepatitis

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 269)
# Related Disease Score Top Affiliating Genes
1 non-a-e hepatitis 32.9 ALB F2
2 hepatitis a 32.4 AFP ALB F2 GPT IFNA2 SERPINA1
3 hepatitis c 31.9 AFP GGT1 GPT HFE IFNA1 IFNA2
4 hepatitis e 31.7 ALB CD40LG F2 GPT TNF
5 hepatitis d 31.1 CD40LG F2 GPT IFNA2
6 hepatic coma 30.8 ALB F2 GPT
7 hepatitis 30.2 AFP F2 FASLG GGT1 GPT IFNA1
8 acute liver failure 30.2 ALB F2 GPT SLC17A5
9 bilirubin metabolic disorder 30.1 ALB F2 GGT1 GPT
10 alcohol abuse 30.0 ABCB7 GGT1 GPT SLC17A5
11 protein-energy malnutrition 30.0 ALB GPT TNF
12 hepatitis b 29.9 AFP ALB F2 FGL2 GGT1 GPT
13 peritonitis 29.9 ALB F2 TNF
14 portal hypertension 29.8 ALB F2 GPT TNF
15 alcoholic liver cirrhosis 29.8 ALB F2 SLC17A5 TNF
16 purpura 29.6 CD40LG F2 TNF
17 hepatic encephalopathy 29.6 ALB F2 GPT SLC17A5 TNF
18 arteries, anomalies of 29.6 ALB F2 TLR9 TNF
19 aplastic anemia 29.6 FAS FASLG HFE TNF
20 schistosomiasis 29.5 ALB CD40LG F2 TNF
21 cholecystitis 29.5 ALB F2 GPT KRT18
22 fatty liver disease 29.4 GGT1 GPT HFE KRT18 SLC17A5 TNF
23 scrub typhus 29.4 CD40LG GPT SLC17A5 TNF
24 lichen planus 29.3 MX1 TLR9 TNF
25 alcoholic hepatitis 29.0 ALB F2 GPT KRT18 SLC17A5 TNF
26 autoimmune hepatitis 28.9 CD40LG F2 FAS GGT1 GPT SEPSECS
27 nonalcoholic steatohepatitis 28.9 F2 GPT HFE KRT18 SLC17A5 TNF
28 hepatocellular carcinoma 28.9 AFP ALB F2 FAS FASLG GGT1
29 multiple sclerosis 28.5 FASLG IFNA1 MX1 TLR9 TNF
30 liver cirrhosis 28.4 AFP ALB F2 GGT1 GPT HFE
31 liver disease 27.2 ABCB7 AFP ALB F2 FAS GGT1
32 fulminant viral hepatitis 12.2
33 porphyria cutanea tarda 11.2
34 epstein-barr virus hepatitis 10.9
35 paraquat poisoning 10.6 GPT SLC17A5
36 antipyrine metabolism 10.6 ALB F2
37 lymphomatoid granulomatosis 10.6 IFNA1 IFNA2
38 hepatoportal sclerosis 10.6 F2 GPT
39 pyridoxine deficiency 10.6 GPT SLC17A5
40 squamous papillomatosis 10.5 IFNA1 IFNA2
41 mucinous cystadenofibroma 10.5 AFP SERPINA1
42 polyembryoma 10.5 AFP SERPINA1
43 fascioliasis 10.5 ALB GPT SLC17A5
44 severe hemophilia a 10.5 F2 IFNA1 TNF
45 marburg hemorrhagic fever 10.5 F2 TNF
46 gastroenteritis 10.4 ALB IFNA1 TNF
47 esophageal varix 10.4 AFP ALB F2
48 hepatic vascular disease 10.4 AFP ALB F2
49 vein disease 10.4 AFP ALB F2
50 biliary tract disease 10.4 ALB F2 GGT1

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis

Symptoms & Phenotypes for Viral Hepatitis

MGI Mouse Phenotypes related to Viral Hepatitis:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 SLC17A5 ABCB7 TLR9 AFP TNF ALB
2 liver/biliary system MP:0005370 9.56 KRT18 ABCB7 AFP TNF ALB FAS
3 mortality/aging MP:0010768 9.47 KRT18 SLC17A5 ABCB7 TLR9 AFP TNF

Drugs & Therapeutics for Viral Hepatitis

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 198153-51-4 5360545
2
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 215647-85-1, 99210-65-8
3
Ribavirin Approved Phase 4,Phase 2,Phase 3,Phase 1 36791-04-5 37542
4
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
5
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
6
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
7
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3 154598-52-4 64139
8
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
9
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
10
Pravastatin Approved Phase 4 81093-37-0 54687
11
Simeprevir Approved Phase 4 923604-59-5 66576988
12
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
13
Iron Approved Phase 4 7439-89-6 23925
14
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
15
Emtricitabine Approved, Investigational Phase 4,Phase 2,Phase 3 143491-57-0 60877
16
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 14052 3279
17
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2 54-85-3 3767
18
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
19
Rifampin Approved Phase 4,Phase 2,Phase 3 13292-46-1 5381226 5458213
20
Zidovudine Approved Phase 4,Phase 3,Phase 2 30516-87-1 35370
21
Hydroxocobalamin Approved Phase 4 13422-51-0 5460373 44475014 11953898
22
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
23
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 59-30-3 6037
25
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 10883523 5280795 6221
26
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
27
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4 13422-55-4
28 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
29 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
30 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1
31 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
32 interferons Phase 4,Phase 3,Phase 2,Phase 1
33 Anti-Obesity Agents Phase 4
34 Hepatitis C Antibodies Phase 4,Phase 2
35 insulin Phase 4,Phase 3
36 Insulin, Globin Zinc Phase 4,Phase 3
37 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
38 Anticholesteremic Agents Phase 4
39 Atorvastatin Calcium Phase 4 134523-03-8
40 Calcium, Dietary Phase 4
41 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
42 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
43 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
44 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
45 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1
46 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
47 Reverse Transcriptase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
48 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 2,Phase 3
49 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 2,Phase 3
50 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 347)

# Name Status NCT ID Phase Drugs
1 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
3 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
4 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
5 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
6 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
7 Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B Completed NCT01639066 Phase 4 Tenofovir;Entecavir;Tenofovir
8 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
9 Interferon α 2b Pharmacovigilance Study Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
10 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
11 Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126) Completed NCT00117494 Phase 4 Pravastatin;Rosuvastatin
12 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
13 Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
14 Efficacy of Silymarin for Acute Hepatitis Completed NCT00412763 Phase 4 Silymarin (Silybum marianum)
15 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Completed NCT01327547 Phase 4 Maraviroc;Placebo
16 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
17 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
18 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
19 Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh. Recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
20 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Recruiting NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
21 Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission Recruiting NCT02937779 Phase 4 Tenofovir disoproxil fumarate
22 Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B Active, not recruiting NCT01639092 Phase 4 Tenofovir;Tenofovir;Entecavir
23 Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Active, not recruiting NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
24 Strategic Timing of Antiretroviral Treatment Active, not recruiting NCT00867048 Phase 4 All licensed antiretroviral medications
25 Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients Terminated NCT00122668 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitor
26 Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Terminated NCT00122655 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitors
27 Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C Terminated NCT02120274 Phase 4 Vitamin D;Vitamin B 12
28 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
29 A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 Unknown status NCT02371408 Phase 2, Phase 3 ravidasvir hydrochloride;sofosbuvir;ribavirin
30 A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B Unknown status NCT01172392 Phase 3 Pegylated interferon-alpha-2a;Nucleotidic or Nucleosidic Treatment
31 BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection Unknown status NCT01641016 Phase 2, Phase 3 efavirenz
32 Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C Completed NCT00265642 Phase 3 Irbesartan;placebo
33 Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Completed NCT01595685 Phase 3 Telbivudine;Entecavir
34 Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
35 Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients Completed NCT00946595 Phase 2, Phase 3 efavirenz/emtricitabin/tenofovir;lopinavir/ritonavir
36 Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices Completed NCT00657397 Phase 3 Methadone
37 Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding Completed NCT00640263 Phase 3 lopinavir/ritonavir (LPV/r);Lamivudine (3TC)
38 Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) Completed NCT00573001 Phase 3 Tenofovir/Emtricitabine (Truvada) and Nevirapine;Tenofovir/Emtricitabine/Efavirenz (Atripla);Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia);Tenofovir/Emtricitabine (Truvada) and Zidovudine
39 Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) Completed NCT00495651 Phase 3 Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis;Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis
40 Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) Completed NCT00495326 Phase 2, Phase 3 Nevirapine based therapy;Efavirenz based therapy;Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
41 Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load Completed NCT00454337 Phase 3 FTC/TDF + EFV or LPV/R +T20;FTC/TDF + EFV or LPV/R
42 Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136 Completed NCT00421551 Phase 3 Darunavir;ritonavir
43 Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients Completed NCT00391638 Phase 2, Phase 3 TRUVADA (EMTRICITABINE + TENOFOVIR DF)
44 Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE Completed NCT00383734 Phase 3
45 Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130) Completed NCT00302822 Phase 3 enfuvirtide;emtricitabine/tenofovir;lopinavir or efavirenz
46 Antiretroviral Treatment Simplified Follow-up Management Assessment (ANRS 12110 STRATALL) Completed NCT00301561 Phase 3
47 Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA) Completed NCT00226434 Phase 3
48 Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin Completed NCT00196664 Phase 3 Paroxetine
49 Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART Completed NCT00196612 Phase 3 emtricitabine, FTC (drug);didanosine, ddI (drug);efavirenz (drug)
50 Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213) Completed NCT00158522 Phase 3 pegylated interferon alpha2a

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Genetic Tests for Viral Hepatitis

Anatomical Context for Viral Hepatitis

MalaCards organs/tissues related to Viral Hepatitis:

38
Liver, Testes, Kidney, T Cells, Bone, Brain, Thyroid

Publications for Viral Hepatitis

Articles related to Viral Hepatitis:

(show top 50) (show all 1072)
# Title Authors Year
1
Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. ( 29309052 )
2018
2
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-I+ inhibitors in clinical practice. ( 29391775 )
2018
3
Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. ( 29354656 )
2018
4
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? ( 29443655 )
2018
5
Management of chronic viral hepatitis in the hematological patient. ( 29415584 )
2018
6
Report from the International Conference on Viral Hepatitis - 2017. ( 29369303 )
2018
7
Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. ( 29432255 )
2018
8
Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges. ( 29367206 )
2018
9
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
10
IL-33 induces immunosuppressive neutrophils via a type 2 innate lymphoid cell/IL-13/STAT6 axis and protects the liver against injury in LCMV infection-induced viral hepatitis. ( 29400707 )
2018
11
High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. ( 29399285 )
2018
12
Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. ( 29427537 )
2018
13
Safety of biologic agents for psoriasis in patients with viral hepatitis. ( 29345515 )
2018
14
Viral Hepatitis Recommendations for Solid-Organ Transplant Recipients and Donors. ( 29381580 )
2018
15
A Cross-Sectional Study of Viral Hepatitis Perception among Residents from Southeast and North Regions of Brazil. ( 29364166 )
2018
16
Viral hepatitis: Biomarker for HBV therapy discontinuation. ( 29362470 )
2018
17
Anti-infective potential of catechins and their derivatives against viral hepatitis. ( 29399578 )
2018
18
Statins reduce the risk of liver decompensation and death in chronic viral hepatitis: a propensity score weighted landmark analysis. ( 28940673 )
2017
19
Radiologic Surveillance of Patients with Viral Hepatitis. ( 28903834 )
2017
20
Diagnosis of coinfection by schistosomiasis and viral hepatitis B or C using 1H NMR-based metabonomics. ( 28763497 )
2017
21
The future of liver transplantation for viral hepatitis. ( 28052618 )
2017
22
Viral hepatitis status does not affect survival in patients with hepatocellular carcinoma. ( 28042245 )
2017
23
Acute Non-Fulminant Viral Hepatitis E Presenting with Acute Pancreatitis-An Unusual Presentation. ( 28951695 )
2017
24
Maximizing Donors with Viral hepatitis in the Current Era. ( 28846183 )
2017
25
Epidemiology and pathogenesis of fulminant viral hepatitis in pregnant women: a review. ( 28994560 )
2017
26
T-cell therapy for chronic viral hepatitis. ( 28847469 )
2017
27
Current status and strategies for viral hepatitis control in Korea. ( 28942620 )
2017
28
Type I interferon receptor signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis. ( 29274730 )
2017
29
A Joint Society statement for elimination of viral hepatitis. ( 28051786 )
2017
30
Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. ( 28887164 )
2017
31
Addressing the increasing global burden of viral hepatitis. ( 28848753 )
2017
32
Noninvasive Assessment of Liver Fibrosis Stage Using Ultrasound-Based Shear Wave Velocity Measurements and Serum Algorithms in Patients With Viral Hepatitis B: A Retrospective Cohort Study. ( 28039877 )
2017
33
Myxovirus resistance 1 gene polymorphisms and outcomes of viral hepatitis B and C infections in Moroccan patients. ( 27458866 )
2017
34
Physician perspectives on the management of viral hepatitis and hepatocellular carcinoma in Myanmar. ( 28797080 )
2017
35
Other Iatrogenic Immunodeficiency-associated Lymphoproliferative Disorder, Hodgkin type, following Epstein-Barr Viral Hepatitis in a Patient with Rheumatoid Arthritis. ( 29279493 )
2017
36
A Diagnostic Laboratory-Based Study on Frequency and Distribution of Viral Hepatitis B and C Among Sudanese. ( 29399232 )
2017
37
Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients. ( 28860489 )
2017
38
Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. ( 28758027 )
2017
39
Current status and strategies for the control of viral hepatitis A in Korea. ( 28942621 )
2017
40
Many European countries 'flying blind' in their efforts to eliminate viral hepatitis. ( 28743934 )
2017
41
Predictors of infection in viral-hepatitis related acute liver failure. ( 28875762 )
2017
42
The evolution of the burden of viral hepatitis from 1990 to 2013: still an open challenge to global public health policy. ( 28848754 )
2017
43
Long-term survival after surveillance and treatment in patients with chronic viral hepatitis and hepatocellular carcinoma. ( 29404481 )
2017
44
Protein glycosylation in viral hepatitis-related HCC: Characterization of heterogeneity, biological roles, and clinical implications. ( 28789967 )
2017
45
Age-standardized mortality rates related to viral hepatitis in Brazil. ( 28760138 )
2017
46
Viral hepatitis and liver cancer. ( 28893941 )
2017
47
Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy. ( 28857896 )
2017
48
Combating the wrath of viral hepatitis in India. ( 27834318 )
2016
49
Is there an influence of hepatic steatosis on fibrosis and necroinflammation in young patients with chronic viral hepatitis B? ( 27499150 )
2016
50
Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis. ( 27777893 )
2016

Variations for Viral Hepatitis

Expression for Viral Hepatitis

Search GEO for disease gene expression data for Viral Hepatitis.

Pathways for Viral Hepatitis

Pathways related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 FAS FASLG IFNA1 IFNA2 MX1 TNF
2
Show member pathways
12.62 CD40LG FAS FASLG IFNA1 IFNA2 TNF
3
Show member pathways
12.53 CD40LG FAS FASLG TLR9 TNF
4
Show member pathways
12.41 FAS FASLG IFNA1 IFNA2 TNF
5
Show member pathways
12.35 FAS FASLG IFNA1 IFNA2 TNF
6 12.25 CD40LG FAS FASLG IFNA1 TLR9 TNF
7
Show member pathways
12.24 ALB F2 GGT1 TNF
8
Show member pathways
12.19 FAS FASLG IFNA1 IFNA2 MX1 TLR9
9
Show member pathways
12.18 FAS FASLG KRT18 TNF
10 12.15 CD40LG FAS FASLG TNF
11 12.13 IFNA1 IFNA2 TLR9 TNF
12
Show member pathways
12.12 FAS FASLG IFNA1 IFNA2 TLR9 TNF
13
Show member pathways
12.07 FAS FASLG TLR9 TNF
14
Show member pathways
11.97 IFNA1 IFNA2 MX1 TNF
15
Show member pathways
11.96 FAS FASLG IFNA1 IFNA2 TNF
16
Show member pathways
11.67 CD40LG FASLG TNF
17 11.66 IFNA2 TLR9 TNF
18 11.59 CD40LG TLR9 TNF
19
Show member pathways
11.58 CD40LG FAS FASLG TNF
20 11.44 FAS FASLG TNF
21 11.4 CD40LG TLR9 TNF
22 11.34 AFP ALB F2
23 11.33 FAS FASLG TNF
24
Show member pathways
11.17 FAS FASLG TNF
25 10.47 FAS FASLG TLR9 TNF

GO Terms for Viral Hepatitis

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 AFP ALB CD40LG F2 FAS FASLG
2 external side of plasma membrane GO:0009897 9.55 CD40LG F2 FASLG HFE TNF
3 extracellular space GO:0005615 9.44 AFP ALB CD40LG F2 FASLG GGT1

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 CD40LG FAS IFNA2 TLR9 TNF
2 cellular protein metabolic process GO:0044267 9.84 AFP ALB F2 SERPINA1
3 blood coagulation GO:0007596 9.8 F2 IFNA1 IFNA2 SERPINA1
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.73 FAS FASLG TNF
5 regulation of receptor activity GO:0010469 9.73 CD40LG F2 FASLG IFNA1 IFNA2 TNF
6 apoptotic signaling pathway GO:0097190 9.72 FAS FASLG TNF
7 defense response GO:0006952 9.71 IFNA1 IFNA2 MX1 TNF
8 B cell differentiation GO:0030183 9.7 CD40LG IFNA1 IFNA2
9 type I interferon signaling pathway GO:0060337 9.69 IFNA1 IFNA2 MX1
10 humoral immune response GO:0006959 9.65 IFNA1 IFNA2 TNF
11 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.57 FAS FASLG
12 tumor necrosis factor-mediated signaling pathway GO:0033209 9.55 CD40LG FAS FASLG KRT18 TNF
13 acute-phase response GO:0006953 9.54 F2 HFE SERPINA1
14 B cell proliferation GO:0042100 9.5 CD40LG IFNA1 IFNA2
15 regulation of immunoglobulin secretion GO:0051023 9.43 CD40LG TNF
16 extrinsic apoptotic signaling pathway GO:0097191 9.26 FAS FASLG KRT18 TNF
17 necroptotic signaling pathway GO:0097527 8.8 FAS FASLG TNF

Molecular functions related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor receptor binding GO:0005164 9.13 CD40LG FASLG TNF
2 cytokine activity GO:0005125 9.02 CD40LG FASLG IFNA1 IFNA2 TNF

Sources for Viral Hepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....